HOOKIPA Pharma Inc. operates as a clinical-stage biopharmaceutical firm dedicated to advancing immunotherapies for infectious diseases and various cancers. This endeavor is powered by its proprietary arenavirus platform. Its most advanced infectious disease program, HB-101, is in a randomized, double-blinded Phase II clinical trial, administered to patients awaiting kidney transplantation from cytomegalovirus-positive donors. In oncology, the company's lead candidates, HB-201 and HB-202, are undergoing Phase I/II clinical trials for human papillomavirus 16-positive cancers. Beyond these clinical programs, HOOKIPA's preclinical pipeline includes HB-300 for prostate cancer and HB-700, which aims to target mutated KRAS in pancreatic, colorectal, and lung cancers. The company has also established a strategic collaboration with Gilead Sciences, Inc. for preclinical research. This partnership focuses on evaluating potential vaccine products, leveraging HOOKIPA's replicating and non-replicating technology platforms, for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. Founded in 2011, HOOKIPA Pharma Inc. maintains its corporate headquarters in New York, New York.
